Four fold increase in risk of infectious complications after stem cell transplant with oral mucositis than without. www.mdpi.com/2072-6694/17...

STOP CAR, ON CAR, OFF CAR, SNIP(er) and VIPER(s) and many other strategies! www.nature.com/articles/s41...

Although very rare, some brakes needed for the CARs www.nejm.org/doi/full/10....

A team that is incredibly passionate and tireless.A leadership that’s phenomenal and visionary. United in a common mission to offer hope and bring smiles.A success story of possibilities and resilience on the anniversary of our new BMT program and honored to lead it! today.uconn.edu/2024/12/bone...

Secondary malignancies after CAR-T jamanetwork.com/journals/jam...

Sun. Fog. Dusk. Dawn Science and research Dibble dibble dibble dopp 🩸🩸🩸 #ASHaiku #ASH24 @ash-hematology.bsky.social

Greener looks the grass Soil back to fertile MRD awaits #ASHaiku #ASH24 @ash-hematology.bsky.social

Thanks to @ash-hematology.bsky.social for this feed to catch up #ASH24 in one place! No more FOMO for virtual attendees ✋🏽

Today’s poem is called ‘Needles’.

#ASH24 educational Program 2024. Treasure trove of🩸🩸🩸updates ashpublications.org/hematology/i...

We are hiring ! Looking for a BMT/cell therapy RN for our growing new BMT program. Check out the link - 'Join Our Team today' and scroll to page two for more details or DM me if anyone is interested. health.uconn.edu/jobs

Severe aplastic anemia. ASTCT guidelines 2024 www.astctjournal.org/article/S266...

Yet another CAR-T success story. Obe-cel in B-ALL www.nejm.org/doi/full/10....

An excellent review characterizing the role of imetelstat in lower-risk MDS! ashpublications.org/blood/articl...

ECOG-ACRIN 4151: MCL pts in CR1 with undetectable MRD6 did not benefit from consolidative auto-HCT. Pts who remain MRD+ after induction may benefit from auto-HCT. LBA #ASH24 ash.confex.com/ash/2024/web...

If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW

4-gene prognostic risk classifier (FLT3-ITD, KRAS, NRAS, and TP53) seems to successfully differentiate outcomes among patients with newly diagnosed AML treated with Aza/Ven than ELN 2017/2022 ashpublications.org/blood/articl...

Ph 1 CD7 targeted CAR for R/R AML. Great CR rate (70%) in extensively treated pts. But short DoR without alloSCT. Relapse with CD7 loss ashpublications.org/blood/articl...

Great review on NLPHL haematologica.org/article/down...

Intriguing T-follicular helper (TFH) lymphomas haematologica.org/article/view...

Beyond the blood: expanding CAR-T to solid tumors www.nature.com/articles/s41...

Acute myelopathy following CAR-T ashpublications.org/blood/articl...

Exciting to see #cell therapy #CAR-T making in roads in non-oncology conditions CAR-T for autoimmune disorders www.science.org/content/arti...

I couldn't find a starter pack for the hematology community so I created one: go.bsky.app/8K9pgxU

Oncology starter pack! go.bsky.app/GKXp9Fy

Snapshot @Cell Advances in cancer immunotherapies

Important approval in a difficult to treat cohort leukemia #revumenib, a menin inhibitor, for #relapsedAML with #KMT2Atranslocation in adult and pediatric patients 1 year and older. www.fda.gov/drugs/resour...

From Texas to CT! Growing up fast and a great addition to our family #furrypets #cats #siamesemix

High-resolution of cancer. Unprecedented. A brief review of what we've just learned from 17 new papers in the latest edition of Ground Truths. It's free, open-access. erictopol.substack.com/p/cancer-sci...